Cancer Supportive Care Products Market, By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor

Cancer Supportive Care Products Market, By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cancer supportive care is associated with care given to the patients suffering from various types of cancer. Supportive care is intended for relieving suffering of the patients and improving their quality of life. The main aim of supportive care is to improve the quality of life of the patient. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. High prevalence of cancer, increasing research and development along with increasing investment in biopharmaceutical industry are anticipated to drive the market growth during the forecast period.
Key features of the study:
This report provides in-depth analysis of the Global Cancer Supportive Care Products market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global Cancer Supportive Care Products market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global Cancer Supportive Care Products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Cancer Supportive Care Products market
Detailed Segmentation:
Global Cancer Supportive Care Products Market, By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
Global Cancer Supportive Care Products Market, By Indication:
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
Global Cancer Supportive Care Products Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
Global Cancer Supportive Care Products Market, By Region:
North America
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Drug Class:
Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor
By Indication
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovary Cancer
Melanoma Cancer
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies
By Country
North Africa
Central Africa
South Africa
Company Profiles
Amgen Inc.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Johnson & Johnson Private Ltd.
Merck
Novartis AG
Baxter International
Hoffmann-La Roche Ltd.
Fagron
Teva Pharmaceutical Industries Ltd.
G1 Therapeutics Inc.
APR Applied Pharma Research S.A.
Acacia Pharma
EMD Serono
Kyowa Hakko Kirin Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.